Edwards Lifesciences (EW) EV to EBITDA (2009 - 2026)

Edwards Lifesciences has reported EV to EBITDA for 18 years, with the latest figure at 93.56 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 8.36% year-over-year to 93.56 in Q2 2026; TTM through Jun 2026 was 33.14, a 15.97% increase from a year earlier, with the FY2025 full-year figure at 35.82, up 24.5% from the prior year.
• EV to EBITDA was 93.56 for Q2 2026 at Edwards Lifesciences, up from 89.06 in the prior quarter.
• The five-year high for EV to EBITDA was 299.66 in Q4 2025, with the low at 89.06 in Q1 2026.
• Average EV to EBITDA over 5 years is 142.19, with a median of 126.47 recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: EV to EBITDA plunged 42.86% in 2023, then surged 136.17% in 2025.
• Over 5 years, EV to EBITDA stood at 223.42 in 2022, then slumped by 42.86% to 127.65 in 2023, then retreated by 0.61% to 126.88 in 2024, then soared by 136.17% to 299.66 in 2025, then sank by 68.78% to 93.56 in 2026.
• The last three EV to EBITDA figures came in at 93.56 (Q2 2026), 89.06 (Q1 2026), and 299.66 (Q4 2025), per Business Quant data.